The extent of pulmonary inflammation caused by SARS-CoV-2 infection seems to correlate well with the patient\'s prognosis, but not with the severity of clinical manifestations presented at first evaluation in the emergency department (ED) ([@bib0005], [@bib0015]). Clinically, a non-negligible percentage of patients with mild symptoms on ED arrival may develop acute respiratory distress syndrome over the next hours ([@bib0020]). Therefore, tools to rapidly identify the extent of the ongoing inflammatory processes are essential. Chest CT appears to be the most effective diagnostic tool for COVID-19 pneumonia, and the morphology of the lung lesions seems to correlate with the severity of the inflammatory process ([@bib0005], [@bib0030], [@bib0010]). However, extensive use of CT on patients leads to an increased risk of radiological exposure and, possibly, a high number of negative scans. Recently, Shang et al. suggested that arterial blood gas (ABG) values may correlate with the presence and morphological characteristics of CT lesions ([@bib0025]). If this early evidence were confirmed, ABG, a rapid, inexpensive, and widely used test might become a valuable tool for the preliminary prognostic assessment of patients with SARS-CoV-2 infection in the ED.

This preliminary study was designed to investigate whether an ABG performed on patient arrival in the ED correlates with the extent of the pulmonary inflammatory process and with the prognosis in patients with SARS-CoV-2 infection.

From March 20, 2020, to April 10, 2020, in the ED of the Merano Hospital (Italy), all patients consecutively evaluated for a suspected SARS-CoV-2 infection were subjected to an ABG test and chest CT. ABG was performed in all suspected patients immediately after arrival in the ED. Retrospectively, only patients who tested positive by polymerase chain reaction for SARS-CoV-2 were included in the present study.

ABG values at ED admission were compared both with the volume of lung parenchyma involved in the inflammatory process (calculated as a percentage of the total lung volume) using Pulmo3D® software (Siemens Healthineers, Erlangen, Germany) and with mortality at 28 days.

Seventy-nine consecutive SARS-CoV-2 patients underwent CT and ABG during the study period. The median age of the patients was 68 years (range 61--78), and the majority were male (69.6%). The median percent extension of the pulmonary inflammatory process was 14.3% (5.0%--25.2%). Nine patients (11.4%) died within 28 days of ED evaluation.

Among the ABG indices, PaO2:FiO2 had an inverse correlation with the percent extension of the pulmonary inflammatory process on CT (r = −0.451, p \< 0.001), as did PCO2 (r = −0.294, p = 0.009) and SpO2 (r = −0.444, p \< 0.001), while pH had a direct correlation (r = 0.228, p = 0.044).

Patients who had died at 28 days presented reduced values of PaO2:FiO2 (215 versus 314, p = 0.005), PCO2 (26.6 versus 31.5, p = 0.049), and SpO2 (82.7 versus 92.3, p = 0.003) on arrival in the ED ([Table 1](#tbl0005){ref-type="table"} ).Table 1Arterial blood gas test values in patients enrolled in the study, divided according to the median percentage of the extension of the pulmonary inflammatory process (14.3%).Table 1Parenchymal involvement \< 14.2%Parenchymal involvement \> 14.2%pPatients, n (%)40 (50.6)39 (49.4)Age, years, median (IQR)64 (57--74)72 (65--82)0.010Male, n (%)24 (60.0)31 (79.5)0.087Onset of symptoms, days (IQR)5 (2--10)5 (3--10)0.715Polycomorbidities15 (37.5)28 (71.8)0.003Arterial blood gas test pH7.44 (7.42--7.49)7.45 (7.43--7.48)0.520 PaO2 (mmHg)71.8 (62.5--80.8)62.9 (53.6--73)0.013 PaCO2 (mmHg)35.9 (32.1--38)32.3 (31--36.8)0.080 HCO324 (23.1--26.4)23.9 (21.5--26.6)0.430 PaO2:FiO2 (mmHg)335 (293--365)250 (198--314)\<0.001 SpO295.3 (94.3--97)92.8 (89.1--95.4)0.002Deaths within 28 days2 (5.0)7 (17.9)0.087

The regression cubic spline model revealed that reduced PaO2:FiO2 values are associated with a higher percentage of the lung being involved in the inflammatory process, as detected on CT ([Figure 1](#fig0005){ref-type="fig"} ).Figure 1Restricted cubic spline model of the dose-response relationship between the PiO2:FiO2 values recorded on patient arrival in the ED and the percentage of the volume of lung parenchyma involved in the inflammatory process in patients with SARS-CoV-2 infection. The black line represents the pooled probability of the percentage of lung parenchyma involved in the inflammatory process linked to PiO2:FiO2 values and the grey lines indicate the 95% confidence interval.Figure 1

Preliminary data from this study suggest that values from an ABG test performed upon arrival of a patient with SARS-CoV-2 in the ED may correlate with the extent of the pulmonary inflammatory process and provide indications of the patient\'s prognosis.

The correlation between ABG indices and CT morphological evaluation of patients with COVID-19 pneumonia has recently been reported. Shang et al. demonstrated a moderate correlation between the presence of ground-glass opacities (GGO) and pulmonary fibrosis on the chest CT with the oxygen index and PO2 and a weak correlation with PCO2 ([@bib0025]). These results are in line with the correlations observed in the data from this study, in which a higher percentage of the lung being involved in the inflammatory process, as reconstructed on the CT scan, appears to correlate with decreased oxygenation capacity. The presence of diffuse bilateral GGO, causing exclusion of pulmonary parenchyma (consolidations) and air trapping, has been previously identified in clinically severe patients ([@bib0010]). This could explain the difficulty of oxygenating the blood, even with high FiO2 values, and for this reason, an initially low PaO2:FiO2 index appears to underline the severity of the patient.

Colombi et al. suggested that software-based reconstruction of the quantity of well-ventilated lung at CT (and thus indirectly the severity of the extension of the pulmonary inflammatory process) can improve the estimation of the patient\'s severity compared to the morphological evaluation alone ([@bib0005]).

Reduced ABG values on ED arrival may suggest a greater underlying extension of the inflammatory process and thus identify a patient who may present an increased prognostic risk even if not clinically compromised.

Further confirmatory data are required, but the results of this study suggest that in patients with SARS-CoV-2, the ABG test will be an important tool in the ED due to its rapidity and applicability.
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